News &amp; Updates

The clinical response or survival benefit derived by patients with advanced cutaneous melanoma from adoptive cell therapy with tumor-infiltrating lymphocytes (TIL-ACT) does not wane even with prior antiprogrammed cell death protein 1/programmed death-ligand 1 (anti-PD-[L]1) treatment, according to a study. TIL therapy also provides benefits in the second-line setting after anti-PD-(L)1 treatment.

TIL therapy still effective in advanced melanoma despite prior anti-PD-(L)1 treatment

21 Oct 2024

Histologic EoE control tied to lower chance of stricture development in children

Children with eosinophilic esophagitis (EoE) with a period of histologic disease control and diagnosed at younger ages appear to have reduced odds of developing esophageal strictures, according to a cohort study with >10 years of follow-up.

Histologic EoE control tied to lower chance of stricture development in children

Real-world study favours ritonavir-based regimens for hospitalized COVID-19 patients

In a real-world analysis evaluating four oral antiviral agents for the treatment of COVID-19, two ritonavir-based regimens fared better than molnupiravir and azvudine in reducing hospital stay among patients hospitalized for mild or moderate disease.

Real-world study favours ritonavir-based regimens for hospitalized COVID-19 patients

21 Oct 2024

Complete neurologic recovery key to long-term survival after cardiac arrest

Cardiac arrest survivors who achieve complete neurologic recovery are more likely to have better long-term survival outcomes than those with persistent neurological disabilities, according to a study.

Complete neurologic recovery key to long-term survival after cardiac arrest

1L nab-paclitaxel + S-1 extends PFS and OS vs nab-paclitaxel + gemcitabine in Chinese patients with advanced pancreatic cancer

A phase II trial demonstrated significantly longer progression-free survival (PFS) and overall survival (OS) in Chinese patients with advanced pancreatic cancer (APC) who received first-line treatment with nab-paclitaxel plus S-1 (AS) vs nab-paclitaxel plus gemcitabine (AG).

1L nab-paclitaxel + S-1 extends PFS and OS vs nab-paclitaxel + gemcitabine in Chinese patients with advanced pancreatic cancer

21 Oct 2024

Original New Drug Application Approvals by US FDA (16-30 September 2024)

New drug applications approved by US FDA as of 16-30 September 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-30 September 2024)

Prior local therapy enhances apalutamide’s effect on metastasis-free survival

A secondary post hoc analysis of the phase III SPARTAN trial shows that patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who received prior prostate-directed local therapy (LT) had longer metastasis-free survival (MFS) when treated with apalutamide vs those without prior LT.

Prior local therapy enhances apalutamide’s effect on metastasis-free survival

21 Oct 2024

Sperm fragmentation a risk factor for pregnancy complications

20 Oct 2024 by

High sperm deoxyribonucleic acid fragmentation index (DFI) level appears to negatively affect the outcome of pregnancies achieved with assisted reproductive technology (ART), being linked to increased risks of complications such as preterm birth and pre-eclampsia in a new research.

Sperm fragmentation a risk factor for pregnancy complications

Which imaging mode is more effective in detecting gastric neoplasms?

20 Oct 2024 by

The third-generation narrow-band imaging (3G-NBI) appears better for gastric neoplasm (GN) detection than texture and colour enhancement imaging (TXI) and high-definition white-light imaging (WLI), suggest the results of a phase II study.

Which imaging mode is more effective in detecting gastric neoplasms?

GLP1-RA linked to lower suicide risk among teens with obesity

In the treatment of obesity in adolescents, the incidence of suicidal ideation or attempts appears to be lower among those receiving a glucagon-like peptide 1 receptor agonist (GLP1-RA) than among those undergoing lifestyle intervention alone, according to a retrospective study.

GLP1-RA linked to lower suicide risk among teens with obesity